ArticleInternational journal of colorectal disease2025
Association of lysyl oxidase expression with clinicopathological features in colorectal adenocarcinomas.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The tumor immune microenvironment of thyroid cancer and colorectal cancer: cellular crosstalk and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal adenocarcinoma (CRC) is one of the leading causes of cancer-related mortality worldwide. Within the tumor microenvironment, neoplastic cells, along with tumor-promoting fibroblasts, contribute to the progression of CRC. Lysyl oxidase (LOX), an enzyme involved in this process facilitates collagen cross-linking within the extracellular matrix and plays a crucial role in remodeling the tumor microenvironment (TME) and promoting metastasis through epithelial-mesenchymal transition (EMT). This study investigates LOX expression in both tumor cells and the tumor stroma in relation with clinicopathological features in CRC patients.
methodImmunohistochemical staining of LOX proteins was performed on tissue microarrays from colorectal tumor samples taken from resection specimens. LOX expression was quantified in tumor cells and stroma. The correlation between the expression of LOX and clinicopathological parameters was analyzed.
resultsA positive correlation was observed between peritumoral stromal LOX expression and LOX expression in the tumor epithelium. High expression of LOX in tumor cells was significantly associated with poorer progression-free survival (PFS) among patients. Low tumor budding was observed in tumors with low stromal LOX expression.
conclusionThe current study indicates that LOX may be an important contributor to CRC progression. The findings of this series, in which LOX expression correlated with tumor budding and survival, support a contribution for LOX to EMT and metastasis. Furthermore, LOX expression in both the tumor cell and stromal compartment may add information to improve prognosis in CRC management. These findings, however, have to be validated in further studies, as does also the investigation of LOX as a potential therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.